Plus Therapeutics Inc - Asset Resilience Ratio
Plus Therapeutics Inc (PSTV) has an Asset Resilience Ratio of 17.74% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Plus Therapeutics Inc (PSTV) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Plus Therapeutics Inc's Asset Resilience Ratio has changed over time. See Plus Therapeutics Inc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Plus Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PSTV market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.31 Million | 17.74% |
| Total Liquid Assets | $3.31 Million | 17.74% |
Asset Resilience Insights
- Good Liquidity Position: Plus Therapeutics Inc maintains a healthy 17.74% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Plus Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Plus Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Plus Therapeutics Inc (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Plus Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 53.22% | $3.53 Million | $6.63 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $11.39 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $23.99 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $31.61 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $34.61 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $37.70 Million | -- |
| 2006-12-31 | 15.99% | $3.98 Million | $24.87 Million | -11.84pp |
| 2005-12-31 | 27.83% | $7.84 Million | $28.17 Million | -13.71pp |
| 2004-12-31 | 41.54% | $10.58 Million | $25.47 Million | +0.78pp |
| 2003-12-31 | 40.76% | $11.45 Million | $28.09 Million | -9.79pp |
| 2002-12-31 | 50.55% | $19.88 Million | $39.32 Million | -21.89pp |
| 2001-12-31 | 72.44% | $31.25 Million | $43.14 Million | +1.63pp |
| 2000-12-31 | 70.80% | $37.01 Million | $52.27 Million | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers… Read more